Intellia Therapeutics (NTLA) Equity Ratio (2016 - 2025)
Intellia Therapeutics (NTLA) has disclosed Equity Ratio for 11 consecutive years, with 0.8 as the latest value for Q4 2025.
- On a quarterly basis, Equity Ratio rose 8.9% to 0.8 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.8, a 8.9% increase, with the full-year FY2025 number at 0.8, up 8.9% from a year prior.
- Equity Ratio was 0.8 for Q4 2025 at Intellia Therapeutics, down from 0.81 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.84 in Q1 2023 to a low of 0.73 in Q4 2024.
- A 5-year average of 0.8 and a median of 0.81 in 2021 define the central range for Equity Ratio.
- Peak YoY movement for Equity Ratio: increased 15.37% in 2021, then fell 9.3% in 2024.
- Intellia Therapeutics' Equity Ratio stood at 0.8 in 2021, then rose by 1.15% to 0.81 in 2022, then fell by 0.69% to 0.81 in 2023, then decreased by 9.3% to 0.73 in 2024, then increased by 8.9% to 0.8 in 2025.
- Per Business Quant, the three most recent readings for NTLA's Equity Ratio are 0.8 (Q4 2025), 0.81 (Q3 2025), and 0.8 (Q2 2025).